What it's for (Indications)
- Ruxolitinib is a Janus Kinase (JAK) inhibitor indicated for the treatment of specific hematologic and inflammatory conditions.
- For myelofibrosis (MF), it is approved for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis.
- In polycythemia vera (PV), ruxolitinib is indicated for adults who have had an inadequate response to or are intolerant of hydroxyurea.
- Furthermore, it is approved for the treatment of acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older who are refractory to one or two lines of systemic therapy.
- More recently, ruxolitinib has been indicated for the treatment of chronic graft-versus-host disease (cGVHD) in adult and pediatric patients 12 years and older who are refractory to one or two lines of systemic therapy.
- These indications are based on significant improvements in clinical endpoints such as spleen volume reduction, constitutional symptoms, and overall response rates, as demonstrated in pivotal clinical trials.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of ruxolitinib varies significantly based on the indication, patient's platelet count, renal and hepatic function, and concomitant medications. For myelofibrosis, the starting dose is typically 15 mg orally twice daily for platelet counts between 100-200 x 10^9/L, and 20 mg orally twice daily for platelet counts >200 x 10^9/L. For polycythemia vera, the starting dose is 10 mg orally twice daily. In acute and chronic graft-versus-host disease, the recommended starting dose is 10 mg orally twice daily. Doses must be carefully titrated based on efficacy and tolerability, particularly monitoring for hematologic toxicities like thrombocytopenia, anemia, and neutropenia. Dose reductions are often necessary for patients with impaired renal or hepatic function, or when co-administered with strong CYP3A4 inhibitors, due to increased systemic exposure. Discontinuation or temporary interruption may be required for severe adverse reactions or declining blood counts. It is crucial for healthcare professionals to consult the full prescribing information for detailed dosing schedules, dose adjustment guidelines, and instructions for discontinuation. |
Safety & Warnings
Common Side Effects
- Ruxolitinib therapy is associated with a range of side effects, some of which can be serious.
- Common hematologic adverse reactions include thrombocytopenia, anemia, and neutropenia, which frequently necessitate dose modification or interruption.
- Non-hematologic common side effects often include bruising, dizziness, headache, diarrhea, and weight gain.
- Infections are a significant concern, with patients experiencing increased rates of bacterial, fungal, mycobacterial, and viral infections, particularly herpes zoster and urinary tract infections.
- Serious non-hematologic adverse effects observed in clinical trials and post-marketing surveillance include a heightened risk of major adverse cardiovascular events (MACE), such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
- Thrombotic events, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have also been reported.
- There is an increased incidence of malignancies, including non-melanoma skin cancers and other cancers, and secondary primary malignancies.
- Patients should be closely monitored for these potential complications throughout the course of treatment.
Serious Warnings
- Black Box Warning: Ruxolitinib carries a Black Box Warning, highlighting several serious and potentially life-threatening risks: 1. **Serious Infections:** Patients treated with ruxolitinib are at increased risk for developing serious bacterial, fungal, mycobacterial, and viral infections, including herpes zoster. These infections can lead to hospitalization and death. Healthcare professionals should evaluate patients for tuberculosis and hepatitis B prior to therapy and monitor closely for signs and symptoms of infection during treatment. 2. **Malignancy:** An increased risk of developing malignancies, including lymphoma and non-melanoma skin cancers, has been observed in ruxolitinib-treated patients. Regular skin examinations are recommended. The risk of other cancers is also noted. 3. **Major Adverse Cardiovascular Events (MACE):** An increased risk of major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, has been reported in clinical studies. This risk is particularly relevant in patients with established cardiovascular risk factors. 4. **Thrombosis:** Thrombosis, including deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis, has occurred in ruxolitinib-treated patients. Patients with cardiovascular risk factors should be monitored closely. If symptoms of thrombosis occur, ruxolitinib should be discontinued, and patients should be evaluated promptly. These warnings emphasize the need for careful patient selection, monitoring, and risk management.
- Several critical warnings are associated with ruxolitinib use.
- Serious infections, including bacterial, mycobacterial, invasive fungal, and viral infections (e.
- g.
- , herpes zoster, hepatitis B reactivation), have occurred, some leading to hospitalization or death.
- Patients should be evaluated for tuberculosis and hepatitis B prior to initiation and monitored for signs and symptoms of infection during treatment.
- Hematologic toxicities, such as thrombocytopenia, anemia, and neutropenia, are dose-limiting and require frequent complete blood count monitoring and dose adjustments.
- There is an increased risk of major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke, especially in patients with cardiovascular risk factors.
- Thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, has been reported.
- Malignancies, including lymphoma and non-melanoma skin cancers, have occurred; patients should undergo regular skin examinations.
- Exacerbation of myelofibrosis symptoms, including splenomegaly and constitutional symptoms, may occur upon abrupt discontinuation of ruxolitinib, necessitating gradual tapering.
- Drug interactions, particularly with strong CYP3A4 inhibitors, require dose adjustments.
- Patients should be educated on reporting symptoms promptly.
How it Works (Mechanism of Action)
Ruxolitinib is a selective inhibitor of Janus Kinase (JAK) 1 and JAK2. These kinases are integral components of the JAK-STAT signaling pathway, which is crucial for the signaling of numerous cytokines and growth factors involved in hematopoiesis and immune function, such as erythropoietin, thrombopoietin, granulocyte-colony stimulating factor (G-CSF), and various interleukins (e.g., IL-2, IL-6, IL-7, IL-15). In myelofibrosis and polycythemia vera, the JAK-STAT pathway is often dysregulated, frequently due to mutations (e.g., JAK2 V617F), leading to constitutive activation and uncontrolled cell proliferation, splenomegaly, and debilitating constitutional symptoms. By inhibiting JAK1 and JAK2, ruxolitinib reduces the phosphorylation and activation of STAT proteins, thereby decreasing downstream cytokine-induced signaling. This inhibition leads to a reduction in splenomegaly and amelioration of constitutional symptoms in myelofibrosis and polycythemia vera patients. In graft-versus-host disease, ruxolitinib modulates the immune response by inhibiting cytokine signaling that drives inflammation and T-cell activation, thus mitigating the severity of the disease.
Commercial Brands (Alternatives)
No other brands found for this formula.